Experimental and clinical pharmacology of bretylium tosylate in acute myocardial infarction: a 15-year journey.
Experimental and clinical studies demonstrate the antifibrillatory effectiveness of bretylium tosylate: Experimental ventricular fibrillation induced either by electrical stimulation or by ischemia is prevented by bretylium. In 2,000 acute myocardial infarction patients who received bretylium prophylactically primary ventricular fibrillation occurred in less than 1% of cases. In a randomized hemodynamic study in acute myocardial infarction patients bretylium induced a significant decrease in heart rate, systolic and mean left ventricular pressures, and in systolic and mean aortic pressures. In addition, a parallel and significant decrease in total pulmonary and systemic resistances was seen, accompanied by decreases in tension time and left ventricular (delta P/delta V) indexes. Bretylium tosylate induces stabilization of electrical systole duration (QTc) in acute myocardial infarction patients. The conclusions of the present review strongly support those of the United States Food and Drug Administration, approving bretylium for prophylaxis and treatment of ventricular fibrillation.
D000818:Animals; D001949:Bretylium Compounds / Q000627:therapeutic use*; D001950:Bretylium Tosylate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D014693:Ventricular Fibrillation / Q000209:etiology / Q000517:prevention & control*
D001949:Bretylium Compounds; D001950:Bretylium Tosylate